Ieva Jasiukenaite will take on an important role in defining communication strategy for ZERION and ensure high quality content and news updates for our followers on the website and social media platforms. Ieva joins ZERION with 6+ years of experience working with strategic communication and digital marketing as well as graphical design.
Camila Belavi will support the formulation team in the pre-clinical experimental activities of Dispersome® formulations for ZERION’s drug development programs. Camila joins ZERION with 3+ years of industry experience working with pharmaceutical formulation development including controlled release drug projects with poorly soluble drug compounds and biopolymers.
We are excited to have Ieva and Camila join our team and take part in our journey to commercialize our Dispersome® medicinal products.
January 10, 2022 (COPENHAGEN, Denmark). The Danish drug development company, Zerion Pharma A/S (ZERION) has completed a new animal study (in dogs) that clearly demonstrates the potential of its patented Dispersome®
(Copenhagen, December 21, 2021). ZERION Pharma A/S, a Danish pharmaceutical company, elected Dr. Dorte Arnbjerg to join its board of directors at an extraordinary general meeting held on December 14, 2021.